Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.41 |
| ▸ | MAP3K7 | O43318 | 9/20 | 0.40 |
| ▸ | TAB1 | Q15750 | 9/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30098534 | 1.00 | CYP2A6 (0.43) | CYP2A6LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4695073 | 0.88 | MAP3K7 (0.42) | CYP2A6LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1006461 | 0.83 | CYP2A6 (0.56) | CYP2A6LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL31167180 | 0.83 | CYP2A6 (0.56) | CYP2A6LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12636082 | 0.77 | CYP2A6 (0.41) | CYP2A6MAP3K7TAB1GAAKDM4E | |
| SCHEMBL658960 | 0.77 | AXL (0.42) | CYP2A6AXLMAP3K7TAB1IMPDH2 | |
| SCHEMBL23022152 | 0.75 | CYP2A6 (0.43) | CYP2A6EP300KAT2BKAT8MAP3K7 | |
| SCHEMBL23021840 | 0.75 | CYP2A6 (0.40) | CYP2A6MAP3K7TAB1KDM4EALDH1A1 | |
| SCHEMBL3931535 | 0.75 | CYP2A6 (0.41) | CYP2A6CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL8881790 | 0.71 | CYP2A6 (0.51) | CYP2A6GAAKDM4EALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024201248-A1 | COMPOUNDS AND METHODS FOR DEGRADING GSPT1 | PIN THERAPEUTICS, INC. (KR) | 2024-10-03 | — | — | WO | disclosed |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-8501769-B2 | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof | ABBVIE INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-1931681-B1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS SA (CH) | 2012-11-14 | — | — | EP | disclosed |
| US-20120277259-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-11-01 | — | — | US | disclosed |
| US-20120041011-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-02-16 | — | — | US | disclosed |
| WO-2000075145-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-1999062908-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 1999-12-09 | — | — | WO | disclosed |
| US-5856335-A | GLYCINE PARTIAL AGONISTS. | HOECHST MARION ROUSSEL, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| EP-0581106-B1 | Substituted aminothienopyridines, a process for their preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (US) | 1998-05-20 | — | — | EP | disclosed |
| US-5519032-A | ANTIDEPRESSANTS, ANXIOLYTICS, ANTIEMETICS, ANTIPSYCHOTIC | HOECHST MARION ROUSSEL INC. (US) | 1996-05-21 | — | — | US | disclosed |
| EP-0587048-A2 | Heteroarenylpiperazines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-03-16 | — | — | EP | disclosed |
| EP-0581106-A1 | Substituted aminothienopyridines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-02-02 | — | — | EP | disclosed |
| US-5272148-A | Heteroarenylpiperazines | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-12-21 | — | — | US | disclosed |
| US-5252581-A | Modulators of neurotransmitters | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1993-10-12 | — | — | US | disclosed |
| US-4363909-A | ANTIVIRAL AGENTS | RHONE POULENC INDUSTRIES (FR) | 1982-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041011-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | TRPV1, GPR17, TRPV6 | CYP2A6 698/4885LMNA 3985/4885CYP1A2 949/4885 |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | CYP2A6 1719/4885LMNA 4183/4885CYP1A2 2847/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | CYP2A6 1719/4885LMNA 4183/4885CYP1A2 2847/4885 |
| US-20120277259-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | TRPV1, GPR17, TRPV6 | CYP2A6 733/4885LMNA 4029/4885CYP1A2 1012/4885 |
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | MAP3K9, MAP3K19, MAP3K20 | CYP2A6 3319/4885LMNA 1567/4885CYP1A2 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.